drugset / Trial / NCT05025358
A Study of LP-118 in Patients With Advanced Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced malignancies, including solid tumors and lymphomas. LP-118 is a BCL-2/BCL-XL small molecule inhibitor.
Timeline
- Start
- 2021-09-08
- Primary completion
- 2025-07-09
- Completion
- 2025-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-118 | Small molecule | 50 mg | Oral |
| Subject | LP-118 | Small molecule | 100 mg | Oral |
| Subject | LP-118 | Small molecule | 200 mg | Oral |
| Subject | LP-118 | Small molecule | 300 mg | Oral |
| Subject | LP-118 | Small molecule | 400 mg | Oral |
| Subject | LP-118 | Small molecule | 500 mg | Oral |